Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Sanofi-Aventis Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (369)
ARTG (210)
Prescription medicine registration (33)
Australian public assessment report (AusPar) (32)
Section 14, TGO91 consent (23)
Designation or determination (11)
Prescription medicine decision summary (9)
Prescription medicine evaluation (5)

Date

2026 (1)
2025 (26)
2024 (41)
2023 (48)
2022 (26)
2021 (101)
2020 (61)
2019 (126)
2018 (40)
2017 (22)
2016 (24)
2015 (14)
2014 (22)
2013 (8)
2012 (3)
2010 (2)
2009 (11)
2008 (5)
2007 (12)
2006 (10)
2005 (12)
2004 (5)
2003 (2)
2002 (6)
2001 (3)
2000 (11)
1999 (5)
1998 (4)
1997 (1)
1996 (7)
1995 (2)
1994 (6)
1993 (6)
1991 (19)

Search

Sponsor content

692 result(s) found, displaying 371 to 380

Vaxigrip inactivated influenza vaccine (split virion) 0.5mL injection syringe Cancelled under Section 30(1)(c) of the Act

3 May 2019

Cancellation by sponsor

Requested by Sanofi-Aventis Australia Pty Ltd
VAXIGRIP INFLUENZA VACCINE (split virion) 0.5mL injection syringe Cancelled under Section 30(1)(c) of the Act

3 May 2019

Cancellation by sponsor

Requested by Sanofi-Aventis Australia Pty Ltd
VAXIGRIP JUNIOR inactivated influenza vaccine (split virion) 0.25mL solution for injection syringe Cancelled under Section 30(1)(c) of the Act

3 May 2019

Cancellation by sponsor

Requested by Sanofi-Aventis Australia Pty Ltd
OXYBUTYNIN WINTHROP oxybutynin hydrochloride 5mg tablet bottle Cancelled under Section 30(1)(c) of the Act

8 April 2019

Cancellation by sponsor

Requested by Sanofi-Aventis Australia Pty Ltd
FRUSEMIDE WINTHROP furosemide (frusemide) 20mg tablet bottle Cancelled under Section 30(1)(c) of the Act

8 April 2019

Cancellation by sponsor

Requested by Sanofi-Aventis Australia Pty Ltd
FRUSEMIDE WINTHROP furosemide (frusemide) 40mg tablet bottle Cancelled under Section 30(1)(c) of the Act

8 April 2019

Cancellation by sponsor

Requested by Sanofi-Aventis Australia Pty Ltd
FRUSEMIDE WINTHROP furosemide (frusemide) 10mg/mL oral liquid bottle Cancelled under Section 30(1)(c) of the Act

8 April 2019

Cancellation by sponsor

Requested by Sanofi-Aventis Australia Pty Ltd
FRUSEMIDE WINTHROP furosemide (frusemide) (as sodium) 20mg/2mL injection ampoule Cancelled under Section 30(1)(c) of the Act

8 April 2019

Cancellation by sponsor

Requested by Sanofi-Aventis Australia Pty Ltd
FRUSEMIDE WINTHROP furosemide (frusemide) (as sodium) 40mg/4mL injection ampoule Cancelled under Section 30(1)(c) of the Act

8 April 2019

Cancellation by sponsor

Requested by Sanofi-Aventis Australia Pty Ltd
FRUSEMIDE WINTHROP HIGH DOSE furosemide (frusemide) 250mg/25mL injection ampoule Cancelled under Section 30(1)(c) of the Act

8 April 2019

Cancellation by sponsor

Requested by Sanofi-Aventis Australia Pty Ltd

Pages

First page
Previous page
…
Page 34
Page 35
Page 36
Page 37
Current page 38
Page 39
Page 40
Page 41
Page 42
…
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.